21![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX. NULOJIX (belatacept) for injection, fo HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX. NULOJIX (belatacept) for injection, fo](https://www.pdfsearch.io/img/27c2e4ff235c1bb9d29de0e8bd41aac5.jpg) | Add to Reading ListSource URL: packageinserts.bms.comLanguage: English - Date: 2014-12-04 10:12:40
|
---|
22![Minutes of the Session on Development of a Program for Surveillance of PML at the American Neurological Association Meeting Place: Essex Room, Marriott Hotel, Baltimore MD Date: October 13, 2009 Panel: Eugene Major PhD, Minutes of the Session on Development of a Program for Surveillance of PML at the American Neurological Association Meeting Place: Essex Room, Marriott Hotel, Baltimore MD Date: October 13, 2009 Panel: Eugene Major PhD,](https://www.pdfsearch.io/img/2198981f1d25aa18cb8a0bc4af989987.jpg) | Add to Reading ListSource URL: patients.aan.comLanguage: English - Date: 2009-11-10 12:34:54
|
---|
23![• Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed and can be fatal. Permanently discontinue VOTRIENT in patients developing RPLS. (5.9) • Hypertension including hypertensive crisis has be • Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed and can be fatal. Permanently discontinue VOTRIENT in patients developing RPLS. (5.9) • Hypertension including hypertensive crisis has be](https://www.pdfsearch.io/img/9796186e50833af0e4656e1dc750e04c.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2014-11-19 13:09:31
|
---|
24![Microsoft PowerPoint - A Case Study Using the BRAT Framework and Quantitative Methods for Benefit-Risk Assessment - Final 20131 Microsoft PowerPoint - A Case Study Using the BRAT Framework and Quantitative Methods for Benefit-Risk Assessment - Final 20131](https://www.pdfsearch.io/img/432a8912085b5796befdecf6adc77b55.jpg) | Add to Reading ListSource URL: www.amstat.orgLanguage: English - Date: 2013-11-12 00:22:34
|
---|
25![What’s “hot” about thermogenic agents What’s “hot” about thermogenic agents](https://www.pdfsearch.io/img/416760f8592f8dba884a2ae5110fe22e.jpg) | Add to Reading ListSource URL: dpic.orgLanguage: English - Date: 2014-11-10 15:46:29
|
---|
26![Neuroradiological, clinical and genetic characterization of new forms of hereditary leukoencephalopathies Principal Investigator: Dr. Donatella Tampieri, MD, FRCPC, Department of Neuroradiology, Montreal Neurological Ins Neuroradiological, clinical and genetic characterization of new forms of hereditary leukoencephalopathies Principal Investigator: Dr. Donatella Tampieri, MD, FRCPC, Department of Neuroradiology, Montreal Neurological Ins](https://www.pdfsearch.io/img/297b551e00df396a6e5b4b2ea5961895.jpg) | Add to Reading ListSource URL: www.car.caLanguage: English - Date: 2013-06-07 13:56:11
|
---|
27![Reversible leukoencephalopathy associated with cerebral amyloid angiopathy U. Oh, R. Gupta, J. W. Krakauer, A. G. Khandji, S. S. Chin and M. S.V. Elkind Neurology 2004;62;[removed]This information is current as of Septemb Reversible leukoencephalopathy associated with cerebral amyloid angiopathy U. Oh, R. Gupta, J. W. Krakauer, A. G. Khandji, S. S. Chin and M. S.V. Elkind Neurology 2004;62;[removed]This information is current as of Septemb](https://www.pdfsearch.io/img/b59cc3c9d413b5a78998610271975b27.jpg) | Add to Reading ListSource URL: blam-lab.orgLanguage: English - Date: 2012-07-26 22:31:06
|
---|
28![Initial REMS Approval: June[removed]BLA[removed]NULOJIX (belatacept) Selective T-cell costimulation blocker Bristol-Myers Squibb (BMS) Company Initial REMS Approval: June[removed]BLA[removed]NULOJIX (belatacept) Selective T-cell costimulation blocker Bristol-Myers Squibb (BMS) Company](https://www.pdfsearch.io/img/e7250c6a3965f1f3d05cfdb97b075186.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
29![RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of](https://www.pdfsearch.io/img/3dabbc364a78b4ecb1d8310ad43d732d.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-03-31 14:51:38
|
---|
30![Possible mechanisms of the disease Possible mechanisms of the disease](https://www.pdfsearch.io/img/5c510c189524aee7643fa5694293f744.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|